Rocket Pharmaceuticals In... (RCKT)
Rocket Pharmaceuticals Statistics
Share Statistics
Rocket Pharmaceuticals has 106.63M shares outstanding. The number of shares has increased by 17.46% in one year.
| Shares Outstanding | 106.63M |
| Shares Change (YoY) | 17.46% |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 98.92M |
| Failed to Deliver (FTD) Shares | 1.19K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 13.3M, so 12.47% of the outstanding shares have been sold short.
| Short Interest | 13.3M |
| Short % of Shares Out | 12.47% |
| Short % of Float | 22.73% |
| Short Ratio (days to cover) | 2.7 |
Valuation Ratios
The PE ratio is -4.61 and the forward PE ratio is -4.77. Rocket Pharmaceuticals's PEG ratio is 0.71.
| PE Ratio | -4.61 |
| Forward PE | -4.77 |
| PS Ratio | 0 |
| Forward PS | 1 |
| PB Ratio | 2.57 |
| P/FCF Ratio | -5.68 |
| PEG Ratio | 0.71 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Rocket Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.3, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.3 |
| Quick Ratio | 9.3 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.09 |
| Debt / FCF | -0.12 |
| Interest Coverage | 144.86 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-865.37K |
| Employee Count | 299 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -66.09% in the last 52 weeks. The beta is 1, so Rocket Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | -66.09% |
| 50-Day Moving Average | 7.76 |
| 200-Day Moving Average | 14.05 |
| Relative Strength Index (RSI) | 56.69 |
| Average Volume (20 Days) | 2.36M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -273.2M |
| Net Income | -258.75M |
| EBITDA | -273.2M |
| EBIT | -260.63M |
| Earnings Per Share (EPS) | -2.73 |
Balance Sheet
The company has 163.63M in cash and 25.5M in debt, giving a net cash position of 138.14M.
| Cash & Cash Equivalents | 163.63M |
| Total Debt | 25.5M |
| Net Cash | 138.14M |
| Retained Earnings | -1.22B |
| Total Assets | 527.7M |
| Working Capital | 337.5M |
Cash Flow
In the last 12 months, operating cash flow was -209.72M and capital expenditures 0, giving a free cash flow of -209.72M.
| Operating Cash Flow | -209.72M |
| Capital Expenditures | 0 |
| Free Cash Flow | -209.72M |
| FCF Per Share | -2.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RCKT is $47, which is 515.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $47 |
| Price Target Difference | 515.2% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
The last stock split was on Jan 5, 2018. It was a backward split with a ratio of 1:4.
| Last Split Date | Jan 5, 2018 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 3.1 |
| Piotroski F-Score | 3 |